

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



[[PANUMCODE]]

Evrysdi Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date:** {{TODAY}}
Patient's ID {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, **NPI#:** _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

- What is the diagnosis?
 Spinal muscular atrophy
 Other _____
- What is the ICD-10 code? _____
- Please indicate the patient's weight: _____ kg
- Please indicate the daily dose (in milligrams) being prescribed: _____ mg
- Which type of spinal muscular atrophy does the patient have?
 Type 0
 Type 1
 Type 2
 Type 3
 Type 4
 Unknown
- Is the patient dependent on either of the following?
 Invasive ventilation or tracheostomy
 Use of non-invasive ventilation beyond naps and nighttime sleep
 Patient is not dependent on invasive ventilation, tracheostomy, or use of non-invasive ventilation beyond naps and nighttime sleep
- Is the requested drug prescribed by or in consultation with a physician who specializes in treatment of spinal muscular atrophy? Yes No
- Will the requested drug be used concomitantly with Spinraza? Yes No
- Is the patient currently receiving treatment with the requested drug? Yes No *If No, skip to #20*
- Was the patient previously established and is re-starting therapy with the requested drug after administration of gene replacement therapy for SMA (e.g., Zolgensma)? *If Yes, skip to #20* Yes No

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Evrysdi SGM - 5/2022.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081
Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

Member Name: {{MEMFIRST}} {{MEMLAST}} **DOB:** {{MEMBERDOB}} **PA Number:** {{PANUMBER}}

11. Has the patient experienced a positive clinical response with the requested drug since pretreatment baseline documented by one of the following assessments? ***ACTION REQUIRED: If Yes, submit medical records (e.g., chart notes) of the most recent (less than 1 month prior to continuation request) assessment using the HINE-2, HFMSE, CHOP-INTEND, MFM32, or BSID-III assessments.***
- Yes, Hammersmith Infant Neurological Exam Part 2 (HINE-2)
 - Yes, Hammersmith Functional Motor Scale Expanded (HFMSE), *skip to #14*
 - Yes, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), *skip to #15*
 - Yes - MFM32, *skip to #16*
 - Yes - BSID-III, *skip to #17*
 - No, *skip to #18*
12. Has the patient experienced any of the following per the most recent HINE-2 assessment (less than 1 month prior to continuation request)?
- Patient exhibited improvement or maintenance of previous improvement of at least a 2 point (or maximal score) increase in ability to kick
 - Patient exhibited improvement or maintenance of previous improvement of at least a 1 point (or maximal score) increase in any other HINE-2 milestone (e.g., head control, rolling, sitting, crawling, standing, or walking) excluding voluntary grasp
 - None of the above, *skip to #18*
13. Has the patient experienced any of the following per the most recent HINE-2 assessment (less than 1 month prior to continuation request)? *If Yes, no further questions*
- Patient exhibited improvement or maintenance of previous improvement in more HINE-2 motor milestones than worsening (net positive improvement)
 - Patient achieved and maintained any new motor milestones when they would otherwise be unexpected to do so (e.g., sit or stand unassisted, walk)
 - None of the above, *skip to #18*
14. Has the patient experienced any of the following per most the recent HFMSE assessment (less than 1 month prior to continuation request)? *If Yes, no further questions*
- Patient exhibited improvement or maintenance of previous improvement of at least a 3-point increase in score
 - Patient achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so
 - None of the above, *skip to #18*
15. Has the patient experienced any of the following per the most recent CHOP-INTEND assessment (less than 1 month prior to continuation request)? *If Yes, no further questions*
- Patient exhibited improvement or maintenance of previous improvement of at least a 4-point increase in score
 - Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so
 - None of the above, *skip to #18*
16. Has the patient experienced an increase in their MFM32 score from baseline and that increase correlates with a clinically significant functional improvement per most recent MFM32 assessment (less than 1 month prior to continuation request)? *If Yes, no further questions* Yes No *If No, skip to #18.*
17. Has the patient exhibited the ability to sit without support for at least 5 seconds after 12 months of treatment per most recent BSID-III (less than 1 month prior to continuation request)? Yes No
18. Was the patient prescribed the requested drug due to clinical worsening after receiving gene replacement therapy (e.g., Zolgensma)? Yes No
19. Has there been stabilization or improvement in clinical status with the requested drug therapy (e.g., impact on motor milestones)? ***ACTION REQUIRED: If Yes, submit medical records (e.g., chart notes) documenting the impact of therapy with the requested drug and no further questions.*** Yes No

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Evrysdi SGM - 5/2022.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}

20. Was the diagnosis of spinal muscular atrophy confirmed by genetic confirmation of 5q SMA homozygous gene mutation, homozygous gene deletion, or compound heterozygote? **ACTION REQUIRED: If Yes, attach a copy of the laboratory report with SMN1 allele genetic test results.** Yes No
21. Has a baseline assessment been completed using one of the following assessment tools (based on patient age and motor ability) to establish baseline motor ability? **ACTION REQUIRED: If Yes, submit medical records (e.g., chart notes) documenting baseline assessment using the HINE-2, HFMSE, CHOP-INTEND, MFM32 or Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III) assessment tools.**
- Yes - Hammersmith Infant Neurological Exam Part 2 (HINE-2)
 - Yes - Hammersmith Functional Motor Scale Expanded (HFMSE)
 - Yes - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
 - Yes - MFM32 (Motor Function Measure 32)
 - Yes - Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III)
 - No
22. What is the patient's age at initiation of the requested drug? _____ years _____ months
23. Has the patient previously received gene replacement therapy for spinal muscular atrophy (e.g., Zolgensma)? Yes No *If No, skip to #28*
24. Has the patient experienced a worsening in clinical status since receiving gene replacement therapy as demonstrated by a decline of minimally clinical important difference from highest score achieved or baseline on one of the following exams (based on member age and motor ability and specific exam)?
- Yes - Hammersmith Infant Neurological Exam Part 2 (HINE-2)
 - Yes - Hammersmith Functional Motor Scale Expanded (HFMSE)
 - Yes - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
 - Yes - MFM32 (Motor Function Measure 32)
 - Yes - Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III)
 - No
25. Has the patient experienced any of the following since receiving gene replacement therapy?
- A decline of at least 2 points on kicking and 1 point on any other milestone (excluding voluntary grasp) from the highest score achieved on HINE-2
 - A decline of at least 3 points from highest score achieved on HFMSE
 - A decline of at least 4 points from highest score achieved on CHOP-INTEND
 - None of the above
26. Has the patient experienced a decline from baseline since receiving gene replacement therapy? *If Yes, no further questions* Yes No
27. Does the patient have the inability to sit without support for more than 5 seconds per item 22 of test since receiving gene replacement therapy? *If Yes, no further questions* Yes No
28. Has the patient received Spinraza previously? Yes No **Date of last dose:** _____

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Evrysdi SGM - 5/2022.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com